Antimicrobial compositions for treating microbial infections
The disclosure provides compounds and methods to treat a microbial or a bacterial pathogenesis, and demonstrates that the S. aureus pigment is a virulence factor and potential novel target for antimicrobial therapy.
1. An antimicrobial pharmaceutical formulation for topical administration comprising:
(a) at least one squalene synthase inhibitor,
(b) at least one antimicrobial; and
(c) a pharmaceutically acceptable carrier,
wherein the at least one squalene synthase inhibitor is or comprises a compound represented by formula I:
wherein:
m is 0, 1, 2 or 3;
n is an integer between 1 and 10 inclusive;
each D and E are each independently selected from the group consisting of: H, aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo;
M 1 , M 2 , and M 3 are each independently selected from the group consisting of metals, ammonium and esters thereof;
R 1 is selected from the group consisting of: H, aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo, or R 1 and R 2 , together with the carbons to which they are bound, can be joined to form a 4 to 7 membered ring or a substituted 4 to 7 membered ring;
R 2 is selected from the group consisting of: H, aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo, or R 2 and R 1 , together with the carbons to which they are bound, can be joined to form a 4 to 7 membered ring or a substituted 4 to 7 membered ring, or R 2 and R 3 , together with the carbons to which they are bound, can be joined to form a 4 to 7 membered ring or a substituted 4 to 7 membered ring;
R 3 is selected from the group consisting of: H, aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo, or R 3 and R 2 , together with the carbons to which they are bound, can be joined to form a 4 to 7 membered ring or a substituted 4 to 7 membered ring, or R 3 and R 4 , together with the carbons to which they are bound, can be joined to form a 4 to 7 membered ring or a substituted 4 to 7 membered ring;
R 4 is selected from the group consisting of: H, aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo, or R 4 and R 3 , together with the carbons to which they are bound, can be joined to form a 4 to 7 membered ring or a substituted 4 to 7 membered ring;
R 5 , R 6 , R 7 , R 8 , and R 9 are each independently selected from the group consisting of: H, aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo;
L 1 is —S—, —SO—, —SO 2 —, —O—, —N(R 19 )—, or —C(R 20 )(R 21 )—; wherein R 19 , R 20 and R 21 are each independently selected from the group consisting of: H, aryl, substituted aryl, alkyl, substituted alkyl, carboxyl, aminocarbonyl, alkylsulfonylaminocarboxyl, alkoxycarbonyl, and halo;
and the antimicrobial pharmaceutical formulation is formulated for topical administration.
2. The antimicrobial pharmaceutical formulation of claim 1 , further comprising ingredients such that it is formulated as a lotion, cream, gel, ointment or spray.
3. The antimicrobial pharmaceutical formulation of claim 1 , further comprising a crtN inhibitor, a diphenylamine, a diphenylamine derivative or an analog thereof.
4. The antimicrobial pharmaceutical formulation of claim 3 , wherein the diphenylamine derivative is a diclofenac sodium, a mefenamic acid or a lobenzarit disodium.
5. The antimicrobial pharmaceutical formulation of claim 1 , further comprising a bisphosphonate.
6. The antimicrobial pharmaceutical formulation of claim 1 , further comprising at least one third active agent or pharmaceutical.
7. The antimicrobial pharmaceutical formulation of claim 6 , wherein the at least one third active agent or pharmaceutical comprises a crtN inhibitor, a crtM inhibitor, a farnesyl diphosphate synthase inhibitor or any combination thereof.
8. The antimicrobial pharmaceutical formulation of claim 1 , wherein the antimicrobial is an antibacterial agent.
9. The antimicrobial pharmaceutical formulation of claim 1 , wherein the antibiotic or antimicrobial comprises: an aminoglycoside; a penicillin; a cephalosporin; a carbapenem; a monobactam; a quinolone; a tetracycline; a glycopeptide; a chloramphenicol; a clindamycin; a trimethoprim; a sulfamethoxazole; a nitrofurantoin; a rifampin; a mupirocin; an amikacin; a gentamicin; a kanamycin; a netilmicin; a t-obramycin; a streptomycin; an azithromycin; a clarithromycin; an erythromycin; an erythromycin; an estolate; an ethylsuccinate; a gluceptatellactobionate; a stearate; a penicillin; a penicillin G; a penicillin V; a methicillin; a nafcillin; an oxacillin; a cloxacillin; a dicloxacillin; an ampicillin; an amoxicillin; a ticarcillin; a carbenicillin; a mezlocillin; an azlocillin; a piperacillin; a cephalothin; a cefazolin; a cefaclor; a cefamandole; a cefoxitin; a cefuiroxime; a cefonicid; a cefmetazole; a cefotetan; a cefprozil; a loracarbef; a cefetamet; a cefoperazone; a cefotaxime; a ceftizoxime; a ceftriaxone; a ceftazidime; a cefepime; a cefixime; a cefpodoxime; a cefsulodin; an i-mipenem; an aztreonam; a fleroxacin; a nalidixic acid; a norfloxacin; a ciprofloxacin; an ofloxacin; an enoxacin; a lomefloxacin; a cinoxacin; a doxycycline; an m-inocycline; a tetracycline; a vancomycin; a teicoplanin; or, any combination thereof.
10. The antimicrobial pharmaceutical formulation of claim 1 , wherein the antimicrobial comprises a vancomycin.
11. The antimicrobial pharmaceutical formulation of claim 1 , wherein the squalene synthase inhibitor compound has the formula:
12. The antimicrobial pharmaceutical formulation of claim 6 , wherein the at least one third active agent or pharmaceutical comprises a second squalene synthase inhibitor.
13. The antimicrobial pharmaceutical formulation of claim 1 , further comprising an inhibitor of a flavohemoglobin;
wherein the inhibitor of the flavohemoglobin is selected from the group consisting of a miconozole, an econozole, a clortrimazole, and a ketoconazole.
14. The antimicrobial pharmaceutical formulation of claim 1 , formulated as a lotion, a cream, or a soap.
15. The antimicrobial pharmaceutical formulation of claim 1 , formulated as a liposome.
16. A catheter comprising an antimicrobial pharmaceutical formulation of claim 1 .
17. A lotion comprising an antimicrobial pharmaceutical formulation of claim 1 .
18. A cream comprising an antimicrobial pharmaceutical formulation of claim 1 .
19. A wipe comprising an antimicrobial pharmaceutical formulation of claim 1 .
20. The antimicrobial pharmaceutical formulation of claim 1 , formulated as a sustained-release preparation.
21. The antimicrobial pharmaceutical formulation of claim 1 , wherein the antimicrobial pharmaceutical formulation is incorporated or contained within a lotion, a cream, a soap or a wipe.
22. The antimicrobial pharmaceutical formulation of claim 1 , wherein the antimicrobial pharmaceutical formulation is incorporated or contained within a liposome.